1. Home
  2. KE vs ADCT Comparison

KE vs ADCT Comparison

Compare KE & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KE
  • ADCT
  • Stock Information
  • Founded
  • KE 1961
  • ADCT 2011
  • Country
  • KE United States
  • ADCT Switzerland
  • Employees
  • KE N/A
  • ADCT N/A
  • Industry
  • KE Electrical Products
  • ADCT Biotechnology: Pharmaceutical Preparations
  • Sector
  • KE Technology
  • ADCT Health Care
  • Exchange
  • KE Nasdaq
  • ADCT Nasdaq
  • Market Cap
  • KE 459.3M
  • ADCT 380.2M
  • IPO Year
  • KE N/A
  • ADCT 2020
  • Fundamental
  • Price
  • KE $29.37
  • ADCT $4.08
  • Analyst Decision
  • KE Strong Buy
  • ADCT Strong Buy
  • Analyst Count
  • KE 1
  • ADCT 6
  • Target Price
  • KE $28.00
  • ADCT $7.60
  • AVG Volume (30 Days)
  • KE 208.9K
  • ADCT 1.2M
  • Earning Date
  • KE 11-05-2025
  • ADCT 11-06-2025
  • Dividend Yield
  • KE N/A
  • ADCT N/A
  • EPS Growth
  • KE N/A
  • ADCT N/A
  • EPS
  • KE 0.68
  • ADCT N/A
  • Revenue
  • KE $1,486,727,000.00
  • ADCT $77,246,000.00
  • Revenue This Year
  • KE N/A
  • ADCT $13.47
  • Revenue Next Year
  • KE $4.02
  • ADCT $5.88
  • P/E Ratio
  • KE $43.22
  • ADCT N/A
  • Revenue Growth
  • KE N/A
  • ADCT 15.73
  • 52 Week Low
  • KE $12.41
  • ADCT $1.05
  • 52 Week High
  • KE $33.19
  • ADCT $4.74
  • Technical
  • Relative Strength Index (RSI)
  • KE 53.21
  • ADCT 52.28
  • Support Level
  • KE $28.07
  • ADCT $4.02
  • Resistance Level
  • KE $29.26
  • ADCT $4.31
  • Average True Range (ATR)
  • KE 0.99
  • ADCT 0.30
  • MACD
  • KE -0.08
  • ADCT -0.06
  • Stochastic Oscillator
  • KE 59.55
  • ADCT 18.90

About KE Kimball Electronics Inc.

Kimball Electronics Inc is a contract electronic manufacturing services company. The company is engaged in producing durable electronics for the automotive, medical, industrial, and public safety end markets. The company's engineering, manufacturing, and supply chain services utilize common production and support capabilities. It is also engaged in producing safety-critical electronic assemblies for its automotive customers. Geographically, it has business units located in the United States, China, Mexico, Poland, Romania, and Thailand. The company derives maximum revenue from Mexico.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: